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Case repOrt
In situations when a patient's antibody detection test is negative, 
many institutions have moved from an indirect antiglobulin 
test (IAT) crossmatch to an electronic crossmatch system. Here 
we report a case of an acute hemolytic transfusion reaction 
attributable to anti-Dia in a patient with a negative antibody 
detection test. A 22-year-old female patient with a diagnosis 
of β thalassemia and sickle cell anemia commenced a routine 
exchange transfusion of 5 units of red blood cells (RBCs) in the 
apheresis unit as part of her regular treatment. When the patient 
started receiving the implicated unit, she reported back pain, chest 
pain, and a feeling of anxiety, suggestive of an acute transfusion 
reaction. The transfusion was ceased and an investigation of 
an adverse event was commenced. This case illustrates that 
the presence of antibodies to low-prevalence antigens remains 
a significant issue for transfusion-dependent individuals. To 
prevent other transfusion reactions by anti-Dia, the addition of 
Di(a+) cells to the reagent RBCs used for the antibody detection 
test along with IAT-crossmatching of donor units for all patients 
with sickle cell disease is recommended. Immunohematology 
2017;33:6–8.
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The Diego blood group was first discovered in 1955 and 
was named after the patient who had developed an antibody 
and delivered a baby diagnosed with hemolytic disease of 
the fetus and newborn (HDFN).1 The implicated antibody 
was designated as anti-Dia. In 1967, a second Diego antigen, 
Dib, was reported.2 Since then, 22 Diego antigens have been 
described, but it is the presence or absence of Dia and Dib that 
determines a person’s Diego blood type.3 Dia, Dib, and Wra 
are the most significant antigens of this blood group system.4 
The Diego protein, also known as the SLC4A1 protein, is a 
transmembrane, multi-pass protein that assists in maintaining 
the integrity of the red blood cell (RBC) membrane. SLC4A1 is 
also found in renal tubule cells.3
Case Report
A 22-year-old female patient with a diagnosis of β 
thalassemia and sickle cell anemia was due to receive an 
exchange transfusion of 5 units of RBCs in the apheresis unit. 
Her blood type is group O, D+. The individual was a long-
term patient at our institution and had received 321 units of 
RBCs that were phenotype-matched for the common RBC 
antigens, c, C, e, E, K, Fya, Fyb, Jka, Jkb, M, N, S, and s, over a 
period of 17 years. The patient’s antibody detection test was 
and had always been negative, when performed using column 
agglutination technology (CAT) (Ortho BioVue, Anti-IgG, 
-C3d cassette, Ortho Clinical Diagnostics, Buckinghamshire, 
UK) with Abtectcell 0.8 percent cells (bioCSL, Melbourne, 
Australia). Because the antibody detection test was negative, 
the RBCs were crossmatched using an electronic crossmatch 
prior to release for transfusion. 
Following the commencement of the exchange procedure, 
as the patient started receiving the first unit of blood, she 
reported back pain, chest pain, and a feeling of anxiety. The 
patient’s blood pressure rose from 95/57 mmHg prior to the 
reaction to 135/105 mmHg, and her pulse rose from 76 bpm 
to 110 bpm. The transfusion was ceased after only 30–40 mL 
of RBCs from the implicated unit had been infused. 
The patient was admitted to the intensive care unit and 
commenced on intravenous fluid, antibiotics, and paracetamol 
for pain, and she was placed on supplemental oxygen support. 
The patient was able to leave the intensive care unit after a 
few days, her hemolysis resolved, and she recommenced her 
exchange transfusion protocol within a few weeks. The patient’s 
pre-transfusion hemoglobin (Hb) was 8.7 g/dL (normal range 
11.5–16.5 g/dL), and the lowest Hb post-transfusion was 7.6 
g/dL. Pre-transfusion lactate dehydrogenase was 364 U/L 
rising to 608 U/L (normal range 120–250 U/L). The post-
transfusion haptoglobin was decreased at 0.06 g/L (normal 
range 0.25–1.8 g/L). There was no evidence of Hb in the urine. 
Blood cultures on patient sample and blood pack  showed no 
growth. 
Results
The recipient’s post-transfusion direct antiglobulin test 
(DAT) was negative, as was the pre-transfusion DAT, by both 
CAT (BioVue Anti-IgG,-C3d, Ortho Clinical Diagnostics) and 
tube Anti-IgG,-C3d (bioCSL). The antibody detection test was 
negative on both the pre-transfusion and post-transfusion 
samples using Abtectcell III 0.8 percent Screening Cells 
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(bioCSL) with BioVue Anti-IgG,-C3d CAT (Ortho Clinical 
Diagnostics).
Compatibility testing by a tube IAT revealed that the 
implicated unit (i.e., the first unit of RBCs) was incompatible 
with a score of 2 (scale 0–4) using a polyethylene glycol–
enhanced tube test (RAMPEG, bioCSL) and Anti-IgG-C3d 
(bioCSL). A pre-transfusion sample, a post-transfusion 
sample, and RBCs from the implicated unit were sent to 
the Australian Red Cross Blood Service Red Cell Reference 
Laboratory for confirmatory testing. 
The reference laboratory detected an antibody to a low-
prevalence antigen, anti-Dia, in both the pre- and post-
transfusion samples, and the implicated unit was typed as 
Di(a+). There was a very weak reaction with the autologous 
cells in the IAT in the patient’s post-transfusion sample (weak-
positive DAT). An eluate prepared from the autologous cells 
contained anti-Dia reactive in the IAT. The pre-transfusion 
sample contained anti-Dia reactive in the IAT and enzyme 
IAT. The reference laboratory confirmed the incompatibility 
between the recipient’s pre- and post-transfusion samples and 
the donor’s RBCs. No other antibodies were detected in the 
saline, IAT, or enzyme IAT. 
Discussion
This case shows an example of an antibody to a low-
prevalence antigen, anti-Dia, that was not detected using 
routine antibody screening methods but became evident 
following a severe immediate hemolytic transfusion reaction. 
There are a few reports of this antibody causing delayed 
hemolytic transfusion reactions (HTRs),5–7 including one 
report from Australia8 where immediate HTRs are rare.
This patient had been transfusion dependent, because 
of thalassemia/sickle cell disease, for most of her life, having 
received over 320 units of phenotype-matched RBCs. The 
patient had never developed an atypical RBC antibody, allowing 
electronic crossmatching to be used for selection of RBC 
units. Dia is characteristically a low-prevalence antigen in the 
Australian donor population; however, the patient must have 
been transfused with a Di(a+) unit at some point previously 
and developed an antibody that remained undetected using 
the routine antibody screening RBCs.
The nature of the hemolysis suggested an acute HTR 
and possibly hyperhemolysis, a condition often reported in 
patients with sickle cell disease following RBC transfusion 
where the hemolysis may extend to the patient’s existing 
RBCs. In this case, although only 30–40 mL of incompatible 
RBCs were transfused, the laboratory findings suggested 
hemolysis of more than just the incompatible, transfused 
RBCs. Hyperhemolytic reactions can occur up to 7 days post-
transfusion, and often RBC antibodies cannot be detected 
when antibodies to low-prevalence antigens are a possible 
cause.9 The treatment of hyperhemolysis syndrome (HS) 
can be difficult and may include ceasing RBC transfusions 
altogether; however, for those patients who are transfusion-
dependent, exchange transfusion along with supportive care 
to prevent further crises may be required.10 Treatment of HS is 
similar to that used for patients experiencing a delayed HTR.9
Dia is found mainly in populations of Mongolian descent. 
It is also found in 36 percent of South American Indians, 12 
percent of Japanese individuals, and 12 percent of Chinese 
individuals, whereas it is rare in white and black individuals 
(0.01%).4 The prevalence of the antigen in other populations 
varies, although one study found 2.6 percent of donors to be 
Di(a+) and, when previously transfused patients were tested 
for the presence of anti-Dia, 1.3 percent of the patients with 
negative antibody screens were found to react with Di(a+) 
cells.11 Dib is found universally in most populations.12
Anti-Dia has been implicated in causing HDFN, as in the 
original case.1 Four cases of HDFN caused by anti-Dia, have 
been reported;12 however, there are few cases of immediate 
HTR involving anti-Dia. A recent Australian case of a patient 
experiencing an immediate HTR following a RBC transfusion 
for anemia illustrates the possibility that antibodies to low-
prevalence antigens, such as Dia, may have become more 
common.8
The changing nature of the Australian donor profile, with 
increasing numbers of donors of Asian descent, suggests that 
antibodies to Dia may become more common, and screening cell 
manufacturers should look to expand the profile of the antigens 
used on reagent screening RBCs to include low-prevalence 
antigens. Testing laboratories need to be aware of the possible 
development of antibodies to low-prevalence antigens at any 
time following RBC transfusion. Since this incident, in our 
institution, all patients with sickle cell disease requiring blood 
transfusion have their donor blood crossmatched against their 
plasma using an IAT, to ensure compatibility against low-
prevalence antigens before the blood is issued. 
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